- Home
- MRNA vs MBLY Comparison
MRNA vs MBLY Comparison
Compare MRNA & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | MBLY |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 9.3B |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MRNA | MBLY |
|---|---|---|
| Price | $25.14 | $11.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 18 |
| Target Price | ★ $33.91 | $19.29 |
| AVG Volume (30 Days) | ★ 10.0M | 4.0M |
| Earning Date | 11-06-2025 | 10-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,232,000,000.00 | $1,938,000,000.00 |
| Revenue This Year | N/A | $15.90 |
| Revenue Next Year | $0.77 | $7.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.61 |
| 52 Week Low | $22.28 | $10.74 |
| 52 Week High | $48.92 | $22.51 |
Technical Indicators
Market Signals| Indicator | MRNA | MBLY |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 45.84 |
| Support Level | $23.92 | $10.93 |
| Resistance Level | $26.00 | $11.87 |
| Average True Range (ATR) | 1.19 | 0.42 |
| MACD | 0.09 | 0.11 |
| Stochastic Oscillator | 72.59 | 68.25 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Others. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.